title: [Part VI. Antiparasitic treatment for Chagas disease].
abstract: As expert consensus has been arisen about universal antiparasitic treatment for all patients infected with Trypanosoma cruzi, most important drugs licensed for Chagas disease treatment are reviewed: nifurtimox and benznidazol, their mechanisms of action, doses, treatment schedules, adverse effects and contraindications. Two other drugs used for Chagas disease treatment, for which a Chilean experience may be exhibited, are allopurinol and itraconazole. Indications for treatment of Chagas disease in immunocompetent patients and immunocompromised hosts are detailed. This chapter refers besides to the evaluation and monitoring of antiparasitic therapy in immunocompromised patients, the availability of drugs and includes various forms facsimiles suggested to perform clinical and laboratory follow up of patients that undergo treatment, indicating the prescribed drug, adverse effects and time of follow up.
authors.affiliation: Comité de Parasitología, Departamento de Enfermedades Emergentes y Re-emergentes, Ministerio de Salud, Chile.
authors.forename: Werner Apt
authors.initials: WA
authors.lastname: B
authors.forename: Ingrid Heitmann
authors.initials: IH
authors.lastname: G
authors.forename: M Isabel Jercic
authors.initials: MI
authors.lastname: L
authors.forename: Leonor Jofré
authors.initials: LJ
authors.lastname: M
authors.forename: Patricia Muñoz C Del
authors.initials: PM
authors.lastname: V
authors.forename: Isabel Noemí
authors.initials: IN
authors.lastname: H
authors.forename: Ana M San Martín
authors.initials: AM
authors.lastname: V
authors.forename: Jorge Sapunar
authors.initials: JS
authors.lastname: P
authors.forename: Marisa Torres
authors.initials: MT
authors.lastname: H
authors.forename: Inés Zulantay
authors.initials: IZ
authors.lastname: A
mesh_terms: D000493:Allopurinol / Q000627:therapeutic use; D000818:Animals; D014355:Chagas Disease / Q000145:classification / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009547:Nifurtimox / Q000627:therapeutic use; D009593:Nitroimidazoles / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000187:drug effects
chemical_list: D007166:Immunosuppressive Agents; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D000493:Allopurinol; D009547:Nifurtimox; C009999:benzonidazole